• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nanobiotix S.A.

    11/16/23 4:02:02 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBTX alert in real time by email
    SC 13G 1 d568772dsc13g.htm SC 13G SC 13G

    CUSIP No. 63009J107

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No.    )1

     

     

    Nanobiotix S.A.

    (Name of Issuer)

    Ordinary Shares, €0.03 nominal value per share

    (Title of Class of Securities)

    63009J107*

    (CUSIP Number)

    November 9, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

     

    *

    This CUSIP Number applies to the Issuer’s American Depositary Shares, each representing one Ordinary Share. No CUSIP Number has been assigned to the Ordinary Shares.

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

    1 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


    CUSIP No. 63009J107

     

      1.    

      NAME OF REPORTING PERSON

     

      Johnson & Johnson Innovation-JJDC, Inc.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      -0-

       6.  

      SHARED VOTING POWER

     

      4,722,560 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      -0-

       8.  

      SHARED DISPOSITIVE POWER

     

      4,722,560 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,722,560 (1)

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.2% (2)

    12.  

      TYPE OF REPORTING PERSON

     

      CO

     

    (1)

    Held as American Depositary Shares, each representing one Ordinary Share.

    (2)

    Based on 46,232,072 Ordinary Shares outstanding as of November 7, 2023, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on November 9, 2023.

     

    2


    CUSIP No. 63009J107

     

      1.    

      NAME OF REPORTING PERSON

     

      Johnson & Johnson

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      New Jersey

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      -0-

       6.  

      SHARED VOTING POWER

     

      4,722,560 (1)

       7.  

      SOLE DISPOSITIVE POWER

     

      -0-

       8.  

      SHARED DISPOSITIVE POWER

     

      4,722,560 (1)

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      4,722,560 (1)

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

      10.2% (2)

    12.  

      TYPE OF REPORTING PERSON

     

      CO

     

    (1)

    Held as American Depositary Shares, each representing one Ordinary Share.

    (2)

    Based on 46,232,072 Ordinary Shares outstanding as of November 7, 2023, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on November 9, 2023.

     

    3


    CUSIP No. 63009J107

     

    SCHEDULE 13G

     

    ITEM 1(a)

    NAME OF ISSUER:

    Nanobiotix S.A.

     

    ITEM 1(b)

    ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

    60 Rue de Wattignies, 75012 Paris, France

     

    ITEM 2(a)

    NAME OF PERSON FILING:

    This statement is being filed by Johnson & Johnson Innovation-JJDC, Inc., a Delaware corporation (“JJDC”), and Johnson & Johnson, a New Jersey corporation (“J&J”). JJDC is a wholly-owned subsidiary of J&J. The securities reported herein as being held by JJDC and J&J are directly beneficially owned by JJDC. J&J may be deemed to indirectly beneficially own the securities that are directly beneficially owned by JJDC. The Joint Filing Agreement between JJDC and J&J is attached hereto as Exhibit A.

     

    ITEM 2(b)

    ADDRESS OF PRINCIPAL BUSINESS OFFICE:

    JJDC: 410 George Street, New Brunswick, NJ 08901

    J&J: One Johnson & Johnson Plaza, New Brunswick, NJ 08933

     

    ITEM 2(c)

    CITIZENSHIP:

    JJDC: Delaware

    J&J: New Jersey

     

    ITEM 2(d)

    TITLE OF CLASS OF SECURITIES:

    Ordinary Shares, €0.03 nominal value per share (“Ordinary Shares”)

     

    ITEM 2(e)

    CUSIP NUMBER:

    63009J107

    This CUSIP Number applies to the Issuer’s American Depositary Shares, each representing one Ordinary Share. No CUSIP Number has been assigned to the Ordinary Shares.

     

    4


    CUSIP No. 63009J107

     

    ITEM 3

    STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C):

    Not applicable.

     

    ITEM 4

    OWNERSHIP:

    The information set forth in the cover pages of this Schedule 13G is incorporated herein by reference.

     

    ITEM 5

    OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

    Not applicable.

     

    ITEM 6

    OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:

    Not applicable.

     

    ITEM 7

    IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY:

    Not applicable.

     

    ITEM 8

    IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:

    Not applicable.

     

    ITEM 9

    NOTICE OF DISSOLUTION OF GROUP:

    Not applicable.

     

    ITEM 10

    CERTIFICATION:

    By signing below the undersigned certify that, to the best of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5


    CUSIP No. 63009J107

     

    SIGNATURE

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 16, 2023

     

    JOHNSON & JOHNSON INNOVATION-JJDC, INC.
    By:  

    /s/ Jill McManus

    Name:   Jill McManus
    Title:   Assistant Treasurer

     

    JOHNSON & JOHNSON
    By:  

    /s/ Marc Larkins

    Name:   Marc Larkins
    Title:   Secretary

     

    6

    Get the next $NBTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBTX

    DatePrice TargetRatingAnalyst
    8/28/2024$12.00Buy
    Guggenheim
    12/8/2023$11.00Outperform
    Leerink Partners
    More analyst ratings

    $NBTX
    SEC Filings

    View All

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    10/1/25 4:15:05 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    9/30/25 4:19:43 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    9/30/25 4:15:03 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

    Treatment was well-tolerated and injection feasibility was confirmed in 13 patients with locally advanced adenocarcinoma of the esophagus85% (11/13) disease control rate (DCR)69% (9/13) objective response rate (ORR); 6 complete responses and 3 partial responsesRecruitment of 17 additional patients is ongoing as planned Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st PARIS and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer

    10/1/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results

    PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2025. Operational Highlights of the 2025 Half Year Period and To Date Expanding clinical development program evaluating the potential broad applicability of JNJ-1900 (NBTXR3) continues to build significant momentum: First patient dosed in the CONVERGE study, a Johnson & Johnson ("J&J")-sponsored randomized

    9/30/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

    Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-163% (26/41) disease control rate ("DCR") and 37% (15/41) objective response rate ("ORR") in evaluable anti-PD-1 naïve patients per RECIST 1.174% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.115.5 months median Overall Survival ("mOS") in evaluable anti-PD-1 naïve patients11.4 months mOS in evaluable anti-PD-1 resistant patientsInvestigators concluded that these promising results warrant further exploration in randomized controlled trials Data presented as a "Top-rated Abstract in Head and Neck Can

    9/29/25 6:30:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Nanobiotix with a new price target

    Guggenheim initiated coverage of Nanobiotix with a rating of Buy and set a new price target of $12.00

    8/28/24 7:51:18 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Nanobiotix with a new price target

    Leerink Partners initiated coverage of Nanobiotix with a rating of Outperform and set a new price target of $11.00

    12/8/23 8:52:29 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1

    Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1Recommended phase 2 dose (RP2D) established at 33% of gross tumor volume (GTV)47.4% (9/19) best observed objective response rate (ORR) in all lesions per RECIST 1.178.9% (15/19) best observed disease control rate (DCR) in all lesions per RECIST 1.114.6 months median Overall Survival (mOS) in all patients treated (n=21)Investigators concluded that these data warrant further investigation in randomized clinical trials as a potential new option for patients with primary cutaneous melanoma naïve or refractory to anti-

    9/17/25 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

    Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival of 23 months from date of diagnosis [95% CI; 17 months – not reached]Median Local Progression-Free Survival of 13.3 months from completion of radiationNotable findings observed in exploratory biomarker analyses include: An association between increased circulating tumor mutational burden (cTMB) and LPFS and OSCA19-9 normalization in 59% of patients in the study, and an association between CA19-9 normalization and OS First patient injected in a new cohort that adds standard-of-care concurre

    5/5/25 2:00:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

    Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable pancreatic cancer to be presented by Principal Investigator Eugene Koay, MD, at ESTRO 2025 on Sunday, May 4th at 11:00 AM EDT / 5:00 PM CESTNanobiotix will host an event on Monday, May 5th at 8:00 AM EDT / 2:00 PM CEST to review the presented results PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expa

    4/30/25 2:00:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/9/24 5:07:50 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/8/24 8:27:02 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nanobiotix S.A. (Amendment)

    SC 13G/A - Nanobiotix S.A. (0001760854) (Subject)

    2/2/24 4:32:27 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBTX
    Leadership Updates

    Live Leadership Updates

    View All

    NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

    PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) --  NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the

    6/12/24 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

    PARIS and CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will report its financial results for half-year ending June 30, 2023, on Tuesday, September 26, 2023, after the close of the US market. This release will be followed by a conference on Wednesday, September 27, 2023, at 8:00 AM EDT / 2:00 PM CEST. During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company's half-year results and provide an update on business activiti

    9/19/23 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

    PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology. "We are pleased to welcome Dr. Kayitalire to our executive leadership team at this pivotal moment for the development and commercialization of potential first-in-class radioenhancer NBTXR3," sa

    9/5/23 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care